In prostate cancer, upregulation of APLN is more frequently occurred in tumor tissues with advanced pathologic stage, metastasis, prostate-specific antigen failure, and shorter biochemical recurrence-free survival [25]. This evidence concerns the gene KLK3 and prostate cancer.